10/538/134

10/936,134 YONG CHU 6-26-2006

$%^STN;HighlightOn=;**HighlightOff=**;

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssptaylc1626

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	FEB 27	New STN AnaVist pricing effective March 1, 2006
NEWS 4	APR 04	STN AnaVist $500 visualization usage credit offered
NEWS 5	MAY 10	CA/CAplus enhanced with 1900-1906 U.S. patent records
NEWS 6	MAY 11	KOREAPAT updates resume
NEWS 7	MAY 19	Derwent World Patents Index to be reloaded and enhanced
NEWS 8	MAY 30	IPC 8 Rolled-up Core codes added to CA/CAplus and USPATFULL/USPAT2
NEWS 9	MAY 30	The F-Term thesaurus is now available in CA/CAplus
NEWS 10	JUN 02	The first reclassification of IPC codes now complete in INPADOC
NEWS EXPRESS		FEBRUARY 15 CURRENT VERSION FOR WINDOWS IS V8.01a, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005. V8.0 AND V8.01 USERS CAN OBTAIN THE UPGRADE TO V8.01a AT http://download.cas.org/express/v8.0-Discover/
NEWS HOURS		STN Operating Hours Plus Help Desk Availability
NEWS LOGIN		Welcome Banner and News Items
NEWS IPC8		For general information regarding STN implementation of IPC 8
NEWS X25		X.25 communication option no longer available after June 2006

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 09:46:48 ON 26 JUN 2006

=> le reg
LE IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> file reg
COST IN U.S. DOLLARS SINCE FILE TOTAL

	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 09:46:57 ON 26 JUN 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 25 JUN 2006 HIGHEST RN 889359-45-9
DICTIONARY FILE UPDATES: 25 JUN 2006 HIGHEST RN 889359-45-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

```
**********************************************************************
*                                                                    *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added,   *
* effective March 20, 2005.  A new display format, IDERL, is now    *
* available and contains the CA role and document type information. *
*                                                                    *
**********************************************************************
```

Structure search iteration limits have been increased. See HELP SLIMITS
for details.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\10936134\10936134.str



chain nodes :
11 12
ring nodes :
1 2 3 4 5 6 7 8 9 10 13 17 18 19 22 23 24 25 26 27
chain bonds :
1-12 10-11 12-13 13-22
ring bonds :
1-2 1-6 2-3 3-4 4-5 4-7 4-10 5-6 7-8 8-9 9-10 13-17 13-19 17-18 18-19
22-23 22-27 23-24 24-25 25-26 26-27
exact/norm bonds :
1-2 1-6 1-12 2-3 3-4 4-5 4-7 4-10 5-6 7-8 8-9 9-10 10-11 13-17 13-19
17-18 18-19
exact bonds :
12-13 13-22
normalized bonds :
22-23 22-27 23-24 24-25 25-26 26-27

G1:X,Ak

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:CLASS 12:CLASS 13:Atom 17:Atom 18:Atom 19:Atom 22:Atom 23:Atom 24:Atom
25:Atom 26:Atom 27:Atom

L1 STRUCTURE UPLOADED

=> d
L1 HAS NO ANSWERS
L1 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

```
=> s l1
SAMPLE SEARCH INITIATED 09:47:19 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -        4 TO ITERATE

100.0% PROCESSED         4 ITERATIONS                                  3 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:            4 TO      200
PROJECTED ANSWERS:               3 TO      163

L2             3 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 09:47:30 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -      114 TO ITERATE

100.0% PROCESSED       114 ITERATIONS                                 66 ANSWERS
SEARCH TIME: 00.00.01

L3            66 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   166.94     167.15

FILE 'CAPLUS' ENTERED AT 09:47:35 ON 26 JUN 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)
```

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

```
FILE COVERS 1907 - 26 Jun 2006  VOL 145 ISS 1
FILE LAST UPDATED: 25 Jun 2006  (20060625/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l3
L4             6 L3

=> d ibib abs hitstr tot
```

Current appl.

L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:534204 CAPLUS
DOCUMENT NUMBER: 141:89006
TITLE: Preparation of pyrrolidine and azetidine compounds as CCR5 antagonists
INVENTOR(S): Yang, Hanbiao; Kazmierski, Wieslaw Mieczyslaw; Aquino, Christopher Joseph
PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA
SOURCE: PCT Int. Appl., 130 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

Glaxo.

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004055016	A1	20040701	WO 2003-US39618	20031212
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003296992	A1	20040709	AU 2003-296992	20031212
EP 1569933	A1	20050907	EP 2003-813415	20031212
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006511552	T2	20060406	JP 2004-560830	20031212
US 2006059284	A1	20060316	US 2005-538134	20050609

PRIORITY APPLN. INFO.: US 2002-433372P P 20021213
WO 2003-US39618 W 20031212

OTHER SOURCE(S): MARPAT 141:89006
GI



I



II



III

AB Title compds. I [R1 = (un)substituted-alkyl, -alkynyl, -cycloalkyl, -heterocyclyl, etc., or R1 and X taken together form a saturated, partially saturated or aromatic 5-6 membered ring having 0-3 heteroatoms selected from O, P, S, or N that is fused to ring A; R2 = OH, halogen (un)substituted-alkyl, -alkoxy, -aryl, -heteroaryl, -cycloalkyl, etc., or two geminal R2s are optionally taken together to from a spiro, saturated, partially saturated or aromatic 5-6 membered ring having 0-3 heteroatoms selected from O, P, S, or N, said fused or spiro ring optionally substituted; R3 = H, halo, cyano, trifluoromethyl, (un)substituted amino, acylamino, alkyl; R9 = H or oxo; X = C1-5 alkylene, optionally substituted with oxo, thioxo, -S(O)t where t = 1 or 2, halogen atoms, or alkyl and optionally containing 1-3 oxygen, nitrogen, sulfur, or phosphorus atoms; Y = carbonyl, thiocarbonyl, 1,2-dioxoethylene, alkyl, alkenyl, etc.; A = saturated, partially saturated, or aromatic 3-7 monocyclic or 8-10 membered bicyclic ring having one ring nitrogen and 0-4 addnl. heteroatoms selected from O, P, S or N; m = 0 or 1, n = 0-5;] and their pharmaceutically acceptable salts are prepared and disclosed as CCR5 antagonists. Thus, II was prepared via condensation of tert-Bu 3-(3,4-dichlorophenyl)-3-(3-oxopropyl)pyrrolidne-1-carboxylate (preparation given) with the amine III followed by deprotection and acylation with 2-furanoyl chloride. I have pIC50 values of ≥5 in assays for CCR5 antagonism. As CCR5 antagonists, I are useful for the treatment of viral infections (particularly HIV infection).

IT **716326-63-5P 716326-64-6P 716326-65-7P**
716326-66-8P 716326-67-9P 716326-68-0P

L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

716326-69-1P 716326-70-4P 716326-71-5P
716326-72-6P 716326-73-7P 716326-74-8P
716326-75-9P 716326-76-0P 716326-77-1P
716326-78-2P 716326-79-3P 716326-80-6P
716326-81-7P 716326-82-8P 716326-83-9P
716326-84-0P 716326-94-2P 716326-95-3P
716326-96-4P 716326-97-5P 716326-98-6P
716326-99-7P 716327-00-3P 716327-01-4P
716327-02-5P 716327-03-6P 716327-04-7P
716327-05-8P 716327-06-9P 716327-07-0P
716327-08-1P 716327-09-2P 716327-10-5P
716327-11-6P 716327-12-7P 716327-13-8P
716327-14-9P 716327-15-0P 716327-16-1P
716327-17-2P 716327-18-3P 716327-19-4P
716327-20-7P 716327-21-8P 716327-22-9P
716328-43-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of pyrrolidine and azetidine derivs. as CCR5 antagonists)

RN 716326-63-5 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 3-(3,4-dichlorophenyl)-3-[3-(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-8-yl)propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 716326-64-6 CAPLUS
CN Pyrrolidine, 3-(3,4-dichlorophenyl)-1-(2-furanylcarbonyl)-3-[3-(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-8-yl)propyl]- (9CI) (CA INDEX NAME)



RN 716326-65-7 CAPLUS
CN Pyrrolidine, 3-(3,4-dichlorophenyl)-1-(2-furanylcarbonyl)-3-[3-(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-8-yl)propyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

CM 1

CRN 716326-64-6
CMF C31 H34 Cl2 N4 O3



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 716326-66-8 CAPLUS
CN Pyrrolidine, 3-(3,4-dichlorophenyl)-1-(5-isoxazolylcarbonyl)-3-[3-(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-8-yl)propyl]- (9CI) (CA INDEX NAME)



RN 716326-67-9 CAPLUS
CN Pyrrolidine, 3-(3,4-dichlorophenyl)-1-(5-isoxazolylcarbonyl)-3-[3-(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-8-yl)propyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 716326-66-8

L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CMF C30 H33 Cl2 N5 O3



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 716326-68-0 CAPLUS
CN Pyrrolidine, 3-(3,4-dichlorophenyl)-3-[3-(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-8-yl)propyl]-1-(1H-pyrrol-2-ylcarbonyl)- (9CI) (CA INDEX NAME)



RN 716326-69-1 CAPLUS
CN Pyrrolidine, 3-(3,4-dichlorophenyl)-3-[3-(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-8-yl)propyl]-1-(1H-pyrrol-2-ylcarbonyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 716326-68-0
CMF C31 H35 Cl2 N5 O2

L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 716326-72-6 CAPLUS
CN Pyrrolidine, 3-(3,4-dichlorophenyl)-1-(2-furanylcarbonyl)-3-[3-[4-oxo-1-[3-(trifluoromethyl)phenyl]-1,3,8-triazaspiro[4.5]dec-8-yl]propyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 716326-71-5
CMF C32 H33 Cl2 F3 N4 O3



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 716326-73-7 CAPLUS
CN Pyrrolidine, 1-(cyclobutylcarbonyl)-3-(3,4-dichlorophenyl)-3-[3-[4-oxo-1-[3-(trifluoromethyl)phenyl]-1,3,8-triazaspiro[4.5]dec-8-yl]propyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 716326-70-4 CAPLUS
CN Pyrrolidine, 3-(3,4-dichlorophenyl)-1-(1-oxopentyl)-3-[3-[4-oxo-1-[3-(trifluoromethyl)phenyl]-1,3,8-triazaspiro[4.5]dec-8-yl]propyl]- (9CI) (CA INDEX NAME)



RN 716326-71-5 CAPLUS
CN Pyrrolidine, 3-(3,4-dichlorophenyl)-1-(2-furanylcarbonyl)-3-[3-[4-oxo-1-[3-(trifluoromethyl)phenyl]-1,3,8-triazaspiro[4.5]dec-8-yl]propyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 716326-74-8 CAPLUS
CN Pyrrolidine, 1-(cyclobutylcarbonyl)-3-(3,4-dichlorophenyl)-3-[3-[4-oxo-1-[3-(trifluoromethyl)phenyl]-1,3,8-triazaspiro[4.5]dec-8-yl]propyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 716326-73-7
CMF C32 H37 Cl2 F3 N4 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 716326-75-9 CAPLUS
CN Pyrrolidine, 3-(3,4-dichlorophenyl)-1-(1-oxopentyl)-3-[3-(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-8-yl)propyl]- (9CI) (CA INDEX NAME)



RN 716326-76-0 CAPLUS
CN Pyrrolidine, 1-(cyclopentylcarbonyl)-3-(3,4-dichlorophenyl)-3-[3-(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-8-yl)propyl]- (9CI) (CA INDEX NAME)



RN 716326-77-1 CAPLUS
CN Pyrrolidine, 1-(cyclobutylcarbonyl)-3-(3,4-dichlorophenyl)-3-[3-(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-8-yl)propyl]- (9CI) (CA INDEX NAME)



RN 716326-78-2 CAPLUS
CN Pyrrolidine, 1-(cyclobutylcarbonyl)-3-(3,4-dichlorophenyl)-3-[3-(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-8-yl)propyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 716326-77-1
CMF C31 H38 Cl2 N4 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 716326-79-3 CAPLUS
CN Pyrrolidine, 1-(cyclobutylcarbonyl)-3-(3,4-dichlorophenyl)-3-[3-[1-(3-methylphenyl)-4-oxo-1,3,8-triazaspiro[4.5]dec-8-yl]propyl]- (9CI) (CA INDEX NAME)



RN 716326-80-6 CAPLUS
CN Pyrrolidine, 1-(cyclobutylcarbonyl)-3-(3,4-dichlorophenyl)-3-[3-[1-(3-methylphenyl)-4-oxo-1,3,8-triazaspiro[4.5]dec-8-yl]propyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 716326-79-3
CMF C32 H40 Cl2 N4 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 716326-81-7 CAPLUS
CN 1,3,8-Triazaspiro[4.5]decan-4-one, 3-acetyl-8-[3-[1-acetyl-3-(3,4-dichlorophenyl)-3-pyrrolidinyl]propyl]-1-(3-methylphenyl)- (9CI) (CA INDEX NAME)



RN 716326-82-8 CAPLUS
CN 1,3,8-Triazaspiro[4.5]decan-4-one, 3-acetyl-8-[3-[1-acetyl-3-(3,4-dichlorophenyl)-3-pyrrolidinyl]propyl]-1-(3-methylphenyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 716326-81-7
CMF C31 H38 Cl2 N4 O3



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 716326-83-9 CAPLUS
CN 1,3,8-Triazaspiro[4.5]decan-4-one, 8-[3-[1-(2-benzoxazolyl)-3-(3,4-dichlorophenyl)-3-pyrrolidinyl]propyl]-1-phenyl- (9CI) (CA INDEX NAME)



RN 716326-84-0 CAPLUS
CN 1,3,8-Triazaspiro[4.5]decan-4-one, 8-[3-[1-(2-benzoxazolyl)-3-(3,4-dichlorophenyl)-3-pyrrolidinyl]propyl]-1-phenyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 716326-83-9
CMF C33 H35 Cl2 N5 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 716326-94-2 CAPLUS
CN Azetidine, 3-(3,4-dichlorophenyl)-3-[3-(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-8-yl)propyl]-1-(phenylsulfonyl)- (9CI) (CA INDEX NAME)



RN 716326-95-3 CAPLUS
CN Formic acid, compd. with 3-(3,4-dichlorophenyl)-3-[3-(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-8-yl)propyl]-1-(phenylsulfonyl)azetidine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 716326-94-2
CMF C31 H34 Cl2 N4 O3 S



CM 2

CRN 64-18-6
CMF C H2 O2

RN 716326-96-4 CAPLUS
CN Azetidine, 3-(3,4-dichlorophenyl)-1-(2-furanylcarbonyl)-3-[3-(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-8-yl)propyl]- (9CI) (CA INDEX NAME)



RN 716326-97-5 CAPLUS
CN Azetidine, 1-(cyclopentylcarbonyl)-3-(3,4-dichlorophenyl)-3-[3-(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-8-yl)propyl]- (9CI) (CA INDEX NAME)



RN 716326-98-6 CAPLUS

CN Pyrrolidine, 3-(3,4-dichlorophenyl)-1-(2-furanylcarbonyl)-3-[2-(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-8-yl)ethyl]- (9CI) (CA INDEX NAME)



RN 716326-99-7 CAPLUS
CN Pyrrolidine, 3-(3,4-dichlorophenyl)-3-[3-(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-8-yl)propyl]-1-(1H-pyrazol-4-ylcarbonyl)- (9CI) (CA INDEX NAME)



RN 716327-00-3 CAPLUS
CN Pyrrolidine, 3-(3,4-dichlorophenyl)-1-[[5-(1,1-dimethylethyl)-2-furanyl]carbonyl]-3-[3-(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-8-yl)propyl]- (9CI) (CA INDEX NAME)



RN 716327-01-4 CAPLUS
CN 1,3,8-Triazaspiro[4.5]decan-4-one, 8-[3-[3-(3,4-dichlorophenyl)-1-(4,5-dihydro-1H-imidazol-2-yl)-3-pyrrolidinyl]propyl]-1-phenyl- (9CI) (CA INDEX NAME)



RN 716327-02-5 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 3-(3,4-dichlorophenyl)-3-[3-[1-(3-methylphenyl)-4-oxo-1,3,8-triazaspiro[4.5]dec-8-yl]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 716327-03-6 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 3-(3,4-dichlorophenyl)-3-[3-[1-(3-methoxyphenyl)-4-oxo-1,3,8-triazaspiro[4.5]dec-8-yl]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 716327-04-7 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 3-(3,4-dichlorophenyl)-3-[3-[4-oxo-1-[4-(trifluoromethyl)phenyl]-1,3,8-triazaspiro[4.5]dec-8-yl]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 716327-05-6 CAPLUS
CN 1,3,8-Triazaspiro[4.5]decan-4-one, 8-[3-[1-(2-benzothiazolyl)-3-(3,4-dichlorophenyl)-3-pyrrolidinyl]propyl]-1-phenyl- (9CI) (CA INDEX NAME)



RN 716327-06-9 CAPLUS
CN 1,3,8-Triazaspiro[4.5]decan-4-one, 8-[3-[1-(1H-benzimidazol-2-yl)-3-(3,4-dichlorophenyl)-3-pyrrolidinyl]propyl]-1-phenyl- (9CI) (CA INDEX NAME)



RN 716327-07-0 CAPLUS
CN Pyrrolidine, 3-(3,4-dichlorophenyl)-3-[3-[1-(3-methylphenyl)-4-oxo-1,3,8-triazaspiro[4.5]dec-8-yl]propyl]-1-(1-oxopentyl)- (9CI) (CA INDEX NAME)



RN 716327-11-6 CAPLUS
CN 1,3,8-Triazaspiro[4.5]decan-4-one, 3-(cyclobutylcarbonyl)-8-[3-[1-(cyclobutylcarbonyl)-3-(3,4-dichlorophenyl)-3-pyrrolidinyl]propyl]-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 716327-12-7 CAPLUS
CN Pyrrolidine, 3-(3,4-dichlorophenyl)-1-(3-methyl-1-oxobutyl)-3-[3-(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-8-yl)propyl]- (9CI) (CA INDEX NAME)



RN 716327-13-8 CAPLUS
CN Pyrrolidine, 1-(cyclopentylcarbonyl)-3-(3,4-dichlorophenyl)-3-[3-[1-(3-methoxyphenyl)-4-oxo-1,3,8-triazaspiro[4.5]dec-8-yl]propyl]- (9CI) (CA INDEX NAME)



RN 716327-08-1 CAPLUS
CN Pyrrolidine, 1-(cyclobutylcarbonyl)-3-(3,4-dichlorophenyl)-3-[3-[1-(3-methoxyphenyl)-4-oxo-1,3,8-triazaspiro[4.5]dec-8-yl]propyl]- (9CI) (CA INDEX NAME)



RN 716327-09-2 CAPLUS
CN Pyrrolidine, 3-(3,4-dichlorophenyl)-3-[3-[1-(3-methoxyphenyl)-4-oxo-1,3,8-triazaspiro[4.5]dec-8-yl]propyl]-1-(1-oxopentyl)- (9CI) (CA INDEX NAME)



RN 716327-10-5 CAPLUS
CN Pyrrolidine, 3-(3,4-dichlorophenyl)-1-(5-isoxazolylcarbonyl)-3-[3-[1-(3-methoxyphenyl)-4-oxo-1,3,8-triazaspiro[4.5]dec-8-yl]propyl]- (9CI) (CA INDEX NAME)



RN 716327-14-9 CAPLUS
CN 1-Pyrrolidinecarboximidic acid, N-cyano-3-(3,4-dichlorophenyl)-3-[3-[1-(3-methylphenyl)-4-oxo-1,3,8-triazaspiro[4.5]dec-8-yl]propyl]-, phenyl ester (9CI) (CA INDEX NAME)



RN 716327-15-0 CAPLUS
CN Pyrrolidine, 1-(cyclopentylcarbonyl)-3-(3,4-dichlorophenyl)-3-[3-[1-(3-methylphenyl)-4-oxo-1,3,8-triazaspiro[4.5]dec-8-yl]propyl]- (9CI) (CA INDEX NAME)



RN 716327-16-1 CAPLUS
CN 1,3,8-Triazaspiro[4.5]decan-4-one, 3-(cyclopentylcarbonyl)-8-[3-[1-(cyclopentylcarbonyl)-3-(3,4-dichlorophenyl)-3-pyrrolidinyl]propyl]-1-(3-methylphenyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 716327-17-2 CAPLUS
CN 1,3,8-Triazaspiro[4.5]decan-4-one, 3-(cyclobutylcarbonyl)-8-[3-[1-(cyclobutylcarbonyl)-3-(3,4-dichlorophenyl)-3-pyrrolidinyl]propyl]-1-(3-methylphenyl)- (9CI) (CA INDEX NAME)



RN 716327-18-3 CAPLUS
CN Pyrrolidine, 3-(4-chlorophenyl)-1-(cyclobutylcarbonyl)-3-[3-[4-oxo-1-[3-(trifluoromethyl)phenyl]-1,3,8-triazaspiro[4.5]dec-8-yl]propyl]- (9CI) (CA INDEX NAME)



RN 716327-19-4 CAPLUS
CN 1,3,8-Triazaspiro[4.5]decan-4-one, 8-[3-[3-(3,4-dichlorophenyl)-1-(1-oxopentyl)-3-pyrrolidinyl]propyl]-3-(1-oxopentyl)-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 716328-43-7 CAPLUS
CN Pyrrolidine, 1-acetyl-3-(3,4-dichlorophenyl)-3-[3-[1-(3-methylphenyl)-4-oxo-1,3,8-triazaspiro[4.5]dec-8-yl]propyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 716327-20-7 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 3-(3,4-dichlorophenyl)-3-[3-(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-8-yl)propyl]-, 4-nitrophenyl ester (9CI) (CA INDEX NAME)



RN 716327-21-8 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 3-(3,4-dichlorophenyl)-3-[3-(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-8-yl)propyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 716327-22-9 CAPLUS
CN Pyrrolidine, 3-(3-chlorophenyl)-1-(2-furanylcarbonyl)-3-[3-(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-8-yl)propyl]- (9CI) (CA INDEX NAME)

102(b)

L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1999:745214 CAPLUS
DOCUMENT NUMBER: 132:131772
TITLE: Investigation of SAR requirements of SR 142801 through an indexed combinatorial library in solution
AUTHOR(S): Raveglia, Luca F.; Vitali, Mauro; Artico, Marco; Graziani, Davide; Hay, Douglas W. P.; Luttmann, Mark A.; Mena, Renzo; Pifferi, Giorgio; Giardina, Giuseppe A. M.
CORPORATE SOURCE: Department of Medicinal Chemistry, SmithKline Beecham S.p.A., Milan, 20021, Italy
SOURCE: European Journal of Medicinal Chemistry (1999), 34(10), 825-833
CODEN: EJMCA5; ISSN: 0223-5234
PUBLISHER: Editions Scientifiques et Medicales Elsevier
DOCUMENT TYPE: Journal
LANGUAGE: English

AB To rapidly gain information on structure-activity relation (SAR) requirements of the human neurokinin 3 (hNK-3) receptor antagonist SR 142801, an indexed combinatorial library was synthesized in solution and screened on the hNK-3 receptor. SAR considerations drawn from binding affinity of combinatorial mixts. were confirmed through the synthesis and biol. evaluation of some individual compds.

IT 256497-28-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(structure-activity relation requirements of SR 142801 as neurokinin 3 receptor antagonists through indexed combinatorial library in solution)

RN 256497-28-6 CAPLUS
CN 1-Piperidinecarboxylic acid, 3-(3,4-dichlorophenyl)-3-[3-(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-8-yl)propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1998:689192 CAPLUS
DOCUMENT NUMBER: 129:330656
TITLE: Preparation of 1-(3-pyrrolidinylalkyl)-4-piperidinecarboxamides as tachykinin antagonists
INVENTOR(S): Burkholder, Timothy P.; Kudlacz, Elizabeth M.; Le Tieu-bihn; Maynard, George D.
PATENT ASSIGNEE(S): Hoechst Marion Roussel Inc., USA
SOURCE: U.S., 93 pp., Cont.-in-part of U.S. 5,635,510.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5824690	A	19981020	US 1997-798664	19970211
ZA 9403091	A	19950112	ZA 1994-3091	19940504
US 5635510	A	19970603	US 1994-332027	19941031
PRIORITY APPLN. INFO.:			US 1993-58606 B2	19930506
			US 1994-225371 B2	19940419
			US 1994-332027 A2	19941031

OTHER SOURCE(S): MARPAT 129:330656
GI



I

AB Title compds. [I; R = G2(CH2)nR2; G1,G2 = CH2 or CO; R1 = (un)substituted Ph, -naphthyl, pyridyl, etc.; R2 = (un)substituted Ph or -pyridyl; Y1 = CONHR5 or CONR6R7; R5 = H, alkyl, (CH2)qNR6R7, etc.; R6,R7 = alkyl; NR6R7 = heterocyclyl; Y2 = (un)substituted phenyl(methyl), -pyridyl, -thienyl; Y1Y2 = atoms to complete a ring; Z = (CH2)2-3; n = 0 or 1; q = 2 or 3] were prepared Thus, 3,4-Cl2C6H3CH2CN was biscondensed with BrCH2CO2Et and the reduced product cyclized to give, after reduction and N-benzoylation, 1-benzoyl-3-(2-hydroxyethyl)-3-(3,4-dichlorophenyl)pyrrolidine. The latter was treated with MeSO2Cl and the product aminated by 4-phenylpiperidine-4-carboxamide (preparation given) to give I (G1 = CH2; R = Bz, R2 = C6H3Cl2-3,4, Y1 = CONH2, Y2 = Ph, Z = CH2CH2). Data for biol. activity of I were given.

IT 167261-54-3P 167261-55-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 1-(3-pyrrolidinylalkyl)-4-piperidinecarboxamides as tachykinin antagonists)

RN 167261-54-3 CAPLUS

L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

CN Pyrrolidine, 3-(3,4-dichlorophenyl)-1-(2,6-dimethoxybenzoyl)-3-[2-(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-8-yl)ethyl]- (9CI) (CA INDEX NAME)



RN 167261-55-4 CAPLUS
CN Pyrrolidine, 1-benzoyl-3-(3,4-dichlorophenyl)-3-[2-(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-8-yl)ethyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1998:604661 CAPLUS
DOCUMENT NUMBER: 129:245045
TITLE: Preparation of 3,3-disubstituted piperidines for treating the conditions associated with an excess of tachykinins
INVENTOR(S): Harrison, Timothy; Swain, Christopher John
PATENT ASSIGNEE(S): Merck Sharp & Dohme Limited, UK
SOURCE: U.S., 17 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5807865	A	19980915	US 1996-733482	19961018
PRIORITY APPLN. INFO.:			GB 1995-21781 A	19951024

OTHER SOURCE(S): MARPAT 129:245045
GI



I

AB The title compds. [I; m = 0-2; n = 1-3 (with the proviso that the sum of m+n = 1-4); X = CR1R2; one of Y, Z = O while the other = H2; Ar = (un)substituted Ph, thienyl, benzothienyl, etc.; R = (un)substituted Ph; R1R2 = (un)substituted 5-6 membered non-aromatic ring which may contain 1-2 groups of NR5, etc.; R5 = H, C1-4 alkyl, etc.], useful in the treatment or prevention of neuropathy, asthma, osteoarthritis, rheumatoid arthritis or migraine, were prepared Thus, reaction of 5-(3-methanesulfonyloxypropyl)-5-(3,4-dichlorophenyl)-1-benzylpiperidin-2-one with 4-acetyl-4-phenylpiperidine.HCl in the presence of K2CO3 in DMF afforded 41% I [Y = O; Z = H2; R = Ph; Ar = 3,4-Cl2C6H3; n = 1; m = 2; X = CR1R2; R1 = Ph; R2 = MeC(O)]. Compds. I are effective at 0.05-10 mg/kg/day in the treatment of the conditions associated with an excess of tachykinins.

IT 213180-01-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 3,3-disubstituted piperidines for treating the conditions associated with an excess of tachykinins)

RN 213180-01-9 CAPLUS
CN Piperidine, 1-benzoyl-3-(3,4-dichlorophenyl)-3-[3-(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-8-yl)propyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1997:375289 CAPLUS
DOCUMENT NUMBER: 127:95200
TITLE: Substituted pyrrolidin-3-yl-alkyl-piperidines useful as tachykinin antagonists
INVENTOR(S): Burkholder, Timothy P.; Kudlacz, Elizabeth M.; Maynard, George D.
PATENT ASSIGNEE(S): Merrell Pharmaceuticals Inc., USA
SOURCE: U.S., 82 pp., Cont.-in-part of U.S. Ser. No. 225,371, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5626418	A	19970603	US 1994-332027	19941031
CN 1124861	A	19960619	CN 1994-192362	19940422
CN 1081635	B	20020327		
ZA 9403091	A	19950112	ZA 1994-3091	19940504
US 5677356	A	19971015	US 1995-477167	19950607
US 5801176	A	19980119	US 1997-795576	19970206
US 5824686	A	19981020	US 1997-798664	19970211
PRIORITY APPLN. INFO.:			US 1993-58606 B2	19930506
			US 1994-225371 B2	19940419
			US 1994-332027 A3	19941031

OTHER SOURCE(S): MARPAT 127:95200
GI



I



II

AB The invention relates to substituted pyrrolidinyl-3-yl-alkyl-piperidines
I

L4 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

[G, G1 = CH2, CO; m = 2, 3; n = 0, 1; Ar1 = (un)substituted Ph, naphthyl, pyridyl, thienyl, or benzo[1,3]dioxan-5-yl; Ar2 = (un)substituted Ph or pyridyl; Y1 = (un)substituted CONH2; Y2 = (un)substituted Ph, naphthyl, pyridyl, thienyl, or CH2Ph; or Y1Y2 = atoms to complete certain Ph-substituted, 5-membered, diazaspiro ring fusions], their stereoisomers,
N-oxides, and pharmaceutically acceptable salts, and processes for prepn. of the same. I are useful for their pharmacol. activities, such as tachykinin antagonism, and esp. substance P and neurokinin A antagonism. Such compds. are indicated for conditions assocd. with neurogenic inflammation and other diseases. For instance, 3-(3,4-dichlorophenyl)-3-(2-hydroxyethyl)pyrrolidine underwent a sequence of amidation with 3,4,5-trimethoxybenzoyl chloride (71%), conversion of the alc. to a methanesulfonate ester (92%), and reaction of the mesylate moiety with 4-phenylpiperidine-4-carboxamide-HCl (71%), to give title compd. II. In an assay for modulation of NKA-induced respiratory effects in guinea pigs,
II at 10 mg/kg reduced dyspnea to 60% of control.
IT 167261-54-3P 167261-55-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrrolidinylalkylpiperidines as tachykinin antagonists)
RN 167261-54-3 CAPLUS
CN Pyrrolidine, 3-(3,4-dichlorophenyl)-1-(2,6-dimethoxybenzoyl)-3-[2-(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-8-yl)ethyl]- (9CI) (CA INDEX NAME)



RN 167261-55-4 CAPLUS
CN Pyrrolidine, 1-benzoyl-3-(3,4-dichlorophenyl)-3-[2-(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-8-yl)ethyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1995:772578 CAPLUS
DOCUMENT NUMBER: 123:198629
TITLE: Preparation of substituted (pyrrolidin-3-ylalkyl)piperidines as tachykinin antagonists
INVENTOR(S): Burkholder, Timothy P.; Le, Tieu-Binh; Kudlacz, Elizabeth M.; Maynard, George D.
PATENT ASSIGNEE(S): Merrell Dow Pharmaceuticals Inc., USA
SOURCE: PCT Int. Appl., 238 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9426735	A1	19941124	WO 1994-US4498	19940422
W: AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, KZ, LK, LU, LV, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, UZ, VN				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2160462	AA	19941124	CA 1994-2160462	19940422
CA 2160462	C	19981215		
AU 9469426	A1	19941212	AU 1994-69426	19940422
AU 678023	B2	19970515		
EP 696280	A1	19960214	EP 1994-917898	19940422
EP 696280	B1	19970924		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
HU 74085	A2	19961128	HU 1995-3153	19940422
JP 09500361	T2	19970114	JP 1994-525453	19940422
JP 3424174	B2	20030707		
AT 158580	E	19971015	AT 1994-917898	19940422
ES 2110761	T3	19980216	ES 1994-917898	19940422
IL 109496	A1	20000726	IL 1994-109496	19940502
ZA 9403091	A	19950112	ZA 1994-3091	19940504
FI 9505258	A	19951130	FI 1995-5258	19951102
FI 113047	B1	20040227		
NO 9504400	A	19960108	NO 1995-4400	19951103
NO 309144	B1	20001218		
PRIORITY APPLN. INFO.:			US 1993-58606 A	19930506
			US 1994-218483 A	19940328
			US 1994-225371 A	19940419
			WO 1994-US4498 W	19940422

OTHER SOURCE(S): MARPAT 123:198629
GI



1



RN 167262-19-3 CAPLUS
CN Pyrrolidine, 1-benzoyl-3-(3,4-dichlorophenyl)-3-[2-(4-oxo-1,3,8-triazaspiro[4.5]dec-8-yl)ethyl]-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).



RN 167262-20-6 CAPLUS
CN Pyrrolidine, 1-benzoyl-3-(3,4-dichlorophenyl)-3-[2-(4-oxo-1,3,8-triazaspiro[4.5]dec-8-yl)ethyl]-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).

L4 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



AB Title compds. I (G1, G2 = CH2, CO; m = 2,3; n = 0,1; Ar1, Y2 = (substituted)aryl, (substituted)heterocyclyl; Ar2 = (substituted)Ph or heterocyclyl; Y1 = (substituted)HNCO, (dialkylamino)carbonyl, N-heterocyclylcarbonyl; Y1Y2 together with the C to which they are attached form a substituted spirocyclyl), or stereoisomers, or salts thereof, are prepared I are claimed for treatment of neurogenic inflammatory diseases, asthma, pain, and cough. 3-(3,4-Dichlorophenyl)-3-(2-hydroxyethyl)pyrrolidine (preparation given) was reacted with 2,4-dimethoxybenzoyl chloride to give 3-(3,4-dichlorophenyl)-1-(2,4-dimethoxybenzoyl)-3-(2-hydroxyethyl)pyrrolidine which in 2 steps was converted to I (G1 = H2C, G2 = CO, m = 2, n = 0, Ar1 = 3,4-Cl2C6H3, Ar2 = 2,4-(MeO)2C6H3, Y1 = H2NCO, Y2 = Ph). Tachykinin antagonism was demonstrated.

IT **167261-54-3P 167261-55-4P 167261-86-1P 167261-87-2P 167261-88-3P 167261-89-4P 167261-90-7P 167261-91-8P 167262-05-7P 167262-06-8P 167262-19-3P 167262-20-6P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of substituted (pyrrolidinylalkyl)piperidines as tachykinin antagonists)

RN 167261-54-3 CAPLUS
CN Pyrrolidine, 3-(3,4-dichlorophenyl)-1-(2,6-dimethoxybenzoyl)-3-[2-(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-8-yl)ethyl]- (9CI) (CA INDEX NAME)



RN 167261-55-4 CAPLUS
CN Pyrrolidine, 1-benzoyl-3-(3,4-dichlorophenyl)-3-[2-(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-8-yl)ethyl]- (9CI) (CA INDEX NAME)



RN 167261-86-1 CAPLUS
CN Pyrrolidine, 3-(3,4-dichlorophenyl)-3-[2-(4-oxo-1,3,8-triazaspiro[4.5]dec-8-yl)ethyl]-1-(3,4,5-trimethoxybenzoyl)- (9CI) (CA INDEX NAME)



RN 167261-87-2 CAPLUS
CN Pyrrolidine, 3-(3,4-dichlorophenyl)-3-[2-(4-oxo-1,3,8-triazaspiro[4.5]dec-1-en-8-yl)ethyl]-1-(3,4,5-trimethoxybenzoyl)- (9CI) (CA INDEX NAME)



RN 167261-88-3 CAPLUS
CN Pyrrolidine, 3-(3,4-dichlorophenyl)-3-[2-(4-fluorophenyl)-2-(4-oxo-1,3,8-triazaspiro[4.5]dec-8-yl)ethyl]-1-(3,4,5-trimethoxybenzoyl)- (9CI) (CA INDEX NAME)



RN 167261-89-4 CAPLUS
CN Pyrrolidine, 3-(3,4-dichlorophenyl)-3-[2-(4-fluorophenyl)-2-[4-oxo-3-(phenylmethyl)-1,3,8-triazaspiro[4.5]dec-8-yl]ethyl]-1-(3,4,5-trimethoxybenzoyl)- (9CI) (CA INDEX NAME)



RN 167261-90-7 CAPLUS
CN Pyrrolidine, 3-(3,4-dichlorophenyl)-3-[2-[2,4-dioxo-3-(phenylmethyl)-1,3,8-triazaspiro[4.5]dec-8-yl]-2-(4-fluorophenyl)ethyl]-1-(3,4,5-trimethoxybenzoyl)- (9CI) (CA INDEX NAME)



RN 167261-91-8 CAPLUS
CN Pyrrolidine, 3-(3,4-dichlorophenyl)-3-[2-(2,4-dioxo-1,3,8-triazaspiro[4.5]dec-8-yl)-2-(4-fluorophenyl)ethyl]-1-(3,4,5-trimethoxybenzoyl)- (9CI) (CA INDEX NAME)



RN 167262-05-7 CAPLUS
CN Pyrrolidine, 3-(3,4-dichlorophenyl)-1-(2,6-dimethoxybenzoyl)-3-[2-(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-8-yl)ethyl]-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).



RN 167262-06-8 CAPLUS
CN Pyrrolidine, 3-(3,4-dichlorophenyl)-1-(2,6-dimethoxybenzoyl)-3-[2-(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-8-yl)ethyl]-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).